Annual report pursuant to Section 13 and 15(d)

Discontinued Operations (Tables)

v3.22.1
Discontinued Operations (Tables)
12 Months Ended
Dec. 31, 2021
Discontinued Operations  
Schedule of components of loss from discontinued operations as reported in our statements of operations and comprehensive loss and assets and liabilities reported as discontinued operations in our condensed balance sheets

​

​

​

​

​

​

    

Year ended

​

​

December 31, 

​

​

2020

(In thousands, except per share data)

​

​

​

Revenue:

 

​

  

Product revenue

​

$

376

Costs and expenses:

​

 

  

Cost of goods sold

​

 

1,332

Research and development

​

 

1,917

Selling, general and administrative

​

 

7,224

Total costs and expenses

​

 

10,473

Loss from discontinued operations

​

 

(10,097)

Other expense, net

​

 

738

Net loss from discontinued operations

​

$

10,835

Basic and diluted net loss per common share from discontinued operations

​

$

(2.87)

Weighted average shares used in computing basic and diluted net loss per common share

​

 

3,773

​

​

​

​

​

​

​

​

​

    

December 31, 

​

​

2021

​

2020

​

​

(In thousands)

Prepaid expenses and other current assets

​

 

12

​

 

181

Discontinued operations – current assets

​

$

12

​

$

181

​

​

​

​

​

​

​

Accounts payable

​

$

782

​

$

1,515

Accrued clinical trials expenses

​

 

—

​

 

80

Accrued sales allowances

​

 

—

​

 

61

Other accrued liabilities

​

 

362

​

 

304

Discontinued operations – current liabilities

​

$

1,144

​

$

1,960